Keep Factually independent
Whether you agree or disagree with our analysis, these conversations matter for democracy. We don't take money from political groups - even a $5 donation helps us keep it that way.
Fact check: Did all of the Biden era subsidies run out to keep the costs low on Medicaid and Medicare
Executive Summary
The short answer is: no — not “all” Biden-era subsidies simply ran out, but several key temporary enhancements to Affordable Care Act (ACA) premium tax credits are scheduled to expire after 2025, which will materially raise costs for many Marketplace enrollees and could leave millions uninsured. The Biden administration expanded subsidies via legislation and administrative action, while separate reforms (like the Inflation Reduction Act) changed Medicare drug pricing; Medicaid financing is governed differently through federal-state arrangements and expansion policies. The situation is a patchwork of expiring provisions, permanent law changes, and ongoing programs — timing and impact vary by program and population [1] [2] [3] [4].
1. What supporters said the Biden moves would do — and what was temporary
The Biden administration and allies increased affordability by enhancing ACA premium subsidies, notably through pandemic-era and follow-on measures that reduced marketplace premiums and increased eligibility generosity. Reporting and analysis from 2021 onward showed these enhancements were designed to be time-limited unless Congress acted to make them permanent, so advocates warned that without further legislation the gains could reverse. The historical record shows these were policy choices to boost coverage quickly, not permanent rewrites of the ACA, and observers flagged the need for legislative permanence to avoid future cliff effects [2] [3].
2. The imminent expiration that matters most for consumers
A September 2025 study projects that the enhanced premium tax credits will expire after 2025, and that expiration would cause nearly 4.8–5 million people to lose marketplace coverage and make plans less affordable for many remaining enrollees. That analysis identifies a clear, dated policy cliff: the specific expansion phase-out is scheduled unless new laws extend or replace it, producing a measurable near-term rise in uninsured rates and premium burdens for affected households. This is the most direct basis for claims that Biden-era subsidy boosts are ending [1].
3. Why the phrase “all subsidies” is misleading
Saying “all of the Biden era subsidies ran out” conflates distinct programs that operate under different legal frameworks. Medicaid funding and eligibility are primarily state-federal arrangements and expansions under the ACA remain in effect, not subject to the same temporary premium tax-credit schedule. Similarly, Medicare benefits are not dependent on ACA marketplace premium tax credits; Medicare’s structure and financing are set separately by statute and administrative rulemaking. Thus, the expiration of one class of subsidies does not equate to an across-the-board loss of federal health supports [5] [6].
4. Medicare drug pricing and separate reforms still in play
The Inflation Reduction Act (IRA) of 2022 instituted permanent changes allowing Medicare to negotiate certain drug prices, an action distinct from marketplace subsidy policy. That law’s negotiation and price-setting mechanisms aimed to lower Medicare drug spending and were implemented through administration rulemaking and scheduled phases; they are not the same as marketplace premium credits and are not slated to “run out” in the same manner. Legal and industry debates continue about IRA impacts, but this program’s timeline and goals differ from the expiring premium subsidies [4] [7].
5. The federal administration’s continuing role and mixed outcomes
The Biden-Harris Administration continued to pursue affordability through a mix of executive actions and program management to strengthen coverage, but administrative steps cannot unilaterally make temporary tax credits permanent. Agencies have improved outreach, plan design, and enforcement efforts, which have incremental effects on access and affordability. These administrative moves are ongoing and can mitigate some harms from expirations, but they cannot substitute for Congress in extending statutory subsidy levels that are scheduled to lapse [3].
6. What advocates, lawmakers and analysts disagree about now
Advocates emphasize the coverage losses and affordability harms projected if enhanced tax credits lapse and press Congress to act quickly. Opponents and fiscal hawks raise concerns about the cost of permanently extending subsidy levels, debating trade-offs in budgetary terms and policy design. Analysts note that outcomes will vary greatly by state, income, and whether people are eligible for Medicaid expansions, so national headline figures can obscure large local differences. The debate is thus political, fiscal, and technical, with clear stakes for millions of Americans [1] [5].
7. Bottom line — what to watch and when
Watch the 2025 legislative calendar and budget negotiations for measures to extend or alter premium tax credits, and follow state-level Medicaid decisions that affect local coverage. Expect continuing discourse about making temporary pandemic-era enhancements permanent versus allowing a phased expiration that would raise costs for Marketplace enrollees. For Medicare, track IRA implementation milestones and regulatory updates on drug negotiation and price-setting. The framing that “all subsidies ran out” is inaccurate: some temporary subsidies are set to expire after 2025, but other Biden-era reforms and existing programs remain in force [1] [4].